30Apr
25Apr
CytoAgents Announces Completion of Cohort 1 Dose-escalation Stage of Clinical Phase 1B to Advance Research on Cytokine Release Syndrome
PITTSBURGH--(BUSINESS WIRE)--CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, core cohort dose-limiting toxicity observation period in its ongoing Phase 1b/2a clinical trial. Following a review of safety and efficacy data, the Safety Review Committee (SRC) has approved dose-escalation to the next, higher planned dose in Cohort 2. “This milestone marks an important step forward in our mission to deliver a safe, effective therapy...
23Apr
Candidly, Fiducius Partner to Offer Student Debt Repayment Benefits
Candidly has partnered with Fiducius, a provider of financial wellness benefits, to add tools for college savings and private student lending to the Fiducius platform. The new relationship will allow Candidly to grow its solutions for planning and paying for college and, in turn, enable Fiducius to reach new employee populations. With the addition of Candidly’s student loan refinancing marketplace, both firms believe the collaboration will drive more value for Fiducius users adjusting their student debt repayment strategy amid ongoing changes...
23Apr